Company profile: Anavex Life Sciences
1.1 - Company Overview
Company description
- Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
Products and services
- ANAVEX®2-73 (blarcamesine): A small-molecule activator of the sigma-1 receptor (SIGMAR1) that treats Alzheimer's disease, Parkinson's disease, and Rett syndrome with oral dosing
- SIGMACEPTOR™ Discovery Platform: A proprietary platform engineered to produce therapeutic candidates for CNS disorders by modulating the sigma-1 receptor (SIGMAR1)
- ANAVEX®3-71: A clinical-stage drug candidate targeting sigma-1 and M1 muscarinic receptors to treat schizophrenia, Alzheimer's disease, and frontotemporal dementia
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Anavex Life Sciences
ArmaGen
HQ: United States
Website
- Description: Provider of therapies and siRNA delivery technologies that penetrate the blood-brain barrier to treat neurological complications of diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArmaGen company profile →
Alector
HQ: United States
Website
- Description: Provider of neuroimmunology- and human genetics-informed antibody therapeutics for neurodegenerative diseases, with a pipeline including AL001 (targets progranulin for frontotemporal dementia with granulin mutation, Phase 3), AL002 (targets TREM2 to enhance microglia for Alzheimer's, Phase 2b), AL101 (increases progranulin for Alzheimer's/Parkinson's, Phase 2), and preclinical ABC candidates ADP027-ABC (GPNMB) and ADP050-ABC (GCase).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alector company profile →
Cognition Therapeutics
HQ: United States
Website
- Description: Provider of neurodegenerative disease therapeutics, developing CT1812, an oral sigma-2 receptor-targeting therapy aimed at slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company conducts clinical trials on CT1812's safety and efficacy and researches sigma-2 receptor modulators to restore neuronal responses and prevent/displace toxic protein buildup in neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognition Therapeutics company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Salvia BioElectronics
HQ: The Netherlands
Website
- Description: Provider of neuromodulation devices for migraine, including a paper-thin implant placed under the skin near nerves associated with migraine to deliver gentle electrical pulses, the MySalvia external device to activate therapy, and the MySalvia app for monitoring and personalized treatment; also exploring bioelectronic therapy for cluster headache.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salvia BioElectronics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Anavex Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Anavex Life Sciences
2.2 - Growth funds investing in similar companies to Anavex Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Anavex Life Sciences
4.2 - Public trading comparable groups for Anavex Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →